@dhovekamp42@InTheTrenches2@PersimmonTI@JacobPlieth@themotleyfool Appreciate this article but the value of their collab with Genentech is worth $3B by itself. Even if you want to discount that to today, prob $1B. $ADAP board not going to accept a $3B deal and Genentech not going to let it go for that if they already bought in for $3B
@10thbody10thbo1@BertrandBio The press release does state Cohort 3 and expansion only. N=4 from July 2020 data cutoff in slide (1CR, 1SD, 2PD). New data from 10 months later (4/5/21) for Cohort 3 = 1CR, 4PD, xSD? =>> X=6SD. So, +5SD with 64% DCR.
@HassanAesthetic @AIMInvestor4 @NatHarooni Best option is to be long across selective names. Do like $BEAM and $CRBU best purely from tech or access to tech licenses. Grabbing prime, base and/or license shares where I can.
@HassanAesthetic @AIMInvestor4 @NatHarooni Although base editing is awesome, they would need to pay ~$10-$12B to buy $BEAM. That may be too rich for them. $CRBU better option to get exposure and licenses to everything else.
@RNAiAnalyst Confused on the wnts. Agree latest offering has them already ITM ($3.00 strike) or close (~$3.87) and 5.5 year exp. But there are outstand ~$9 strike too. Ppl saying 12/31/21 exp. and ~$490ish strike (incorrect?). Which ones are PHIOW? Been buying <$0.75. Thks if u know.